An examination of the efficacy and safety of fenfluramine in adults, children, and adolescents with Dravet syndrome in a real‐world practice setting: A report from the Fenfluramine European Early Access Program
Abstract Objective To examine the efficacy and safety of fenfluramine in patients with Dravet syndrome (DS) in three age groups: <6, 6‐17, and ≥18 years old, treated in a real‐world setting. Methods Patients with DS were treated with fenfluramine in the European Union Early Access Program (EAP)....
Main Authors: | Renzo Guerrini, Nicola Specchio, Ángel Aledo‐Serrano, Milka Pringsheim, Francesca Darra, Thomas Mayer, Antonio Gil‐Nagel, Tilman Polster, Sameer M. Zuberi, Amélie Lothe, Arnold Gammaitoni, Adam Strzelczyk |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-12-01
|
Series: | Epilepsia Open |
Subjects: | |
Online Access: | https://doi.org/10.1002/epi4.12624 |
Similar Items
-
Fenfluramine Add-On Therapy of Dravet Syndrome
by: J Gordon Millichap
Published: (2012-08-01) -
Fenfluramine increases survival and reduces markers of neurodegeneration in a mouse model of Dravet syndrome
by: John Cha, et al.
Published: (2024-02-01) -
Efficacy and safety of fenfluramine in the treatment of Dravet syndrome - literature review
by: Martyna Stefaniak, et al.
Published: (2022-01-01) -
Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first‐line add‐on therapies for seizures in Dravet syndrome: A network meta‐analysis
by: Renzo Guerrini, et al.
Published: (2024-04-01) -
Efficacy and Safety of Fenfluramine in Epilepsy: A Systematic Review and Meta-analysis
by: Payam Tabaee Damavandi, et al.
Published: (2023-02-01)